meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced NSCLC (mNSCLC) - 1st line (L1)
mNSCLC - L1 - all population
5
mNSCLC - L1 - EGFR mutant
mNSCLC - L1 - PDL1 negative
1
mNSCLC - L1 - PDL1 positive
14
mNSCLC - L1 - TMB>10Mb
1
non squamous cell - mNSCLC - L1
non squamous - mNSCLC - L1 - all population
3
non squamous - mNSCLC - L1 - PDL1 positive
non squamous - mNSCLC - L1 - Wild Type (WT)
6
squamous cell - mNSCLC - L1
squamous - mNSCLC - L1 - all population
4
squamous - mNSCLC - L1 - PDL1 positive
squamous - mNSCLC - L1 - Wild Type (WT)
HER inhibitor
EGFR inhibitor
afatinib based treatment
afatinib alone
dacomitinib
erlotinib based treatment
erlotinib alone
gefitinib based treatment
gefitinib alone
naquotinib
VEGF(R) inhibitor
ramucirumab
ramucirumab plus erlotinib
versus all
vs chemotherapy
vs non platinum-based chemotherapy
vs vinca alkaloids
vs vinorelbine
vs vinorelbine and platin
vs platinum-based chemotherapy
vs platinum derivate
vs platinum association
vs docetaxel plus platin
vs gemcitabine plus platin
vs paclitaxel plus carboplatin
vs pemetrexed plus platin
vs Standard of Care (SoC)
vs HER inhibitor
vs EGFR inhibitor
vs erlotinib based treatment
vs placebo plus erlotinib
vs gefitinib based treatment
vs gefitinib alone
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
graph
table
EGM
comparisons
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
click on circles to display study description...
powered by
vis.js Network